Dr. Doerr originally joined the organization in 2004 (under Peregrine Pharmaceuticals). Dr. Doerr’s experience includes protein design, antibody engineering, DNA cloning, and cell line development of stable and large-scale transient transfections. Dr. Doerr has extensive experience in generating cell lines producing a broad variety of molecules including antibodies, antibody and Fc fusion proteins, scFvs, scFV fusions, cytokines, glyco-proteins, and enzymes and generating stable cell lines expressing cell surface receptors for use in bioassays. Dr. Doerr leads the PD Upstream group and has several years of experience in upstream process development including pilot bioreactors at the 200L scale and has transferred multiple client programs to clinical manufacturing. Dr. Doerr earned her Ph.D. from the University of California, Los Angeles, (UCLA) and her BS in Medical Microbiology at California State University, Long Beach (CSULB).